echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Three types of imitation inhalants of Jiming Trust are accepted by CDE

    Three types of imitation inhalants of Jiming Trust are accepted by CDE

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On December 17, Jimin Credential announced that its wholly-owned subsidiary, Jiyu Pharmaceutical Innovation Technology and Drug Research Institute, independently developed the first three types of generic inhalation preparations—levalbuterol hydrochloride aerosol inhalation solution, which has been approved by the National Drug Administration.
    The Center for Drug Evaluation (CDE) of the Bureau accepted

    This is the second product that Jiminxin has entered the inhalation market after terbutaline sulfate atomized inhalation solution


    Compared with ordinary salbutamol, the levosalbutamol hydrochloride aerosol inhalation solution removes the dextrorotate which is more selective for β1 receptors and brings side effects, and only retains the levosalbutamol which is more selective for β2 receptors
    It has the characteristics of small side effects, good curative effect, and small dosage

    As the active ingredient, levalbuterol has a strong affinity for β2 receptors, and β2 receptors are evenly distributed on the large, medium and small airways, so that the levalbuterol has a comprehensive effect on the smooth muscles of the large, medium and small airways, thus playing a consistent role in relaxing the airway smooth muscles


    In 2019, Wang Chen, an academician of the Chinese Academy of Engineering and an expert in respiratory and critical care medicine, published research results in The Lancet, clarifying the prevalence of adult asthma in China: the prevalence of asthma in people aged 20 and above in China is 4.
    Among them, the male prevalence rate is 4.
    6%, the female prevalence rate is 3.
    7%, and the total number of patients is 45.
    7 million (25.
    7 million males and 20 million females)

    The latest data show that there are about 100 million people in China suffering from chronic obstructive pulmonary disease (COPD), and it has become the third leading cause of death among Chinese residents.
    There is one COPD patient in every seven people aged 40 and over

    Inhaled drugs are the first choice for the treatment of asthma and COPD, but the inhaled drug market in China is mostly occupied by multinational pharmaceutical companies.
    In contrast, domestic inhaled drugs started late and have a small market share


    Note: The original text has been deleted

    Reference materials:

    Chen Wang, Jiangying Xu, Lan Yang, et al.
    Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study) a national cross-sectional study.
    Lancet 2018 Vol 391 1706-1717.

    Kewu Huang, Ting Yang, Jiangying Xu, et al.
    Prevalence, risk factors, and management of asthma in China a national cross-sectional study.
    Lancet 2019 Vol 394 407-418.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.